RxDoctor Payments DataLook up a doctor →

Michael Auerbach, MD

Hematology & Oncology · Baltimore, MDNPI 1336199942

Payments from drug & device makers

$301,036in general payments, 2019–2025

Across 816 payments — averaging $368.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AMAG Pharmaceuticals, Inc.$208K
  • Pharmacosmos Therapeutics Inc.$39K
  • Sysmex America, Inc.$30K
  • Whitehall International Inc$4K
  • AstraZeneca$4K
  • Pfizer$2K
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AMAG Pharmaceuticals, Inc.13$207,666
Pharmacosmos Therapeutics Inc.10$39,355
Sysmex America, Inc.2$30,000
Whitehall International Inc2$4,000
AstraZeneca(2 entities)48$3,859
Pfizer55$2,405
Novartis102$1,738
E.r. Squibb & Sons, L.L.C.54$1,136
Johnson & Johnson(2 entities)49$1,042
Amgen48$828
Genentech USA, Inc.37$698
AbbVie28$579
Bristol Myers Squibb26$561
Exelixis Inc.28$530
GSK29$462
Incyte Corporation24$436
Pharmacyclics LLC, An Abbvie Company17$410
Gilead(2 entities)17$407
Merck24$371
Seagen Inc.16$328
Takeda Pharmaceuticals U.S.A., Inc.13$265
Regeneron Healthcare Solutions, Inc.11$256
Taiho Oncology, Inc.10$247
Astellas Pharma US Inc12$242
Sanofi13$234
EMD Serono, Inc.10$228
Beigene USA, Inc.10$222
Covis Pharma GmbH2$212
Daiichi Sankyo Inc.6$161
Eisai Inc.9$158
Array Biopharma Inc8$155
EUSA Pharma (US) LLC7$150
AVEO Pharmaceuticals, Inc.4$128
Baxter Healthcare1$124
Sandoz5$106
Mirati Therapeutics, Inc.4$100
Boehringer Ingelheim4$92
Lilly USA, LLC5$92
Puma Biotechnology, Inc.4$77
Servier Pharmaceuticals LLC3$61
Deciphera Pharmaceuticals Inc.3$61
Fresenius Kabi USA, LLC2$58
Tersera Therapeutics LLC2$52
Myriad Genetic Laboratories, Inc.3$52
Heron Therapeutics, Inc.2$50
Pharmaessentia USA Corporation2$50
American Regent1$49
Tolmar Pharmaceuticals, Inc.2$42
Ipsen Biopharmaceuticals, Inc2$35
Coherus Oncology, Inc.2$29
Menarini Silicon Biosystems, Inc.1$28
Foundation Medicine, Inc.2$25
ASD Specialty Healthcare, LLC2$25
Sumitomo Pharma America, Inc.1$25
G1 Therapeutics, Inc.1$25
Sanofi-aventis U.S. LLC1$23
Portola Pharmaceuticals, LLC1$23
Acrotech Biopharma Inc.1$21
Sun Pharmaceutical Industries Inc.1$20
Agios Pharmaceuticals, Inc.1$20

How this compares

$301,036 in reported general payments places this provider in the 75th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$2,250,819
Medicare patients
546
Services billed
129,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Baltimore

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →